Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

• Turn Therapeutics Returns to Nasdaq to Highlight Its Progress Since Its October 2025 Direct Listing

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with members of the Turn Therapeutics management team, at Nasdaq's invitation to mark its progress to date.

"We're honored that Nasdaq invited us back to share our story," said Bradley Burnam, Founder and Chief Executive Officer of Turn Therapeutics. "Over the past year we've made meaningful progress, but what I'm most proud of is that we got here by refusing to believe there was only one way to build a biotech company. Turn Therapeutics was founded on the principle that patients deserve targeted, localized therapies rather than systemic treatment whenever possible. We challenged conventional thinking in our science, in how we built the company, and in how we came to the public markets. I hope our story reminds other entrepreneurs that 'the usual way' isn't the only way."

Overview of Event Details

Nasdaq Bell Ringing Ceremony

• Event Date: Monday, August 10, 2026
• Time: The Closing Bell ceremony will be broadcast live beginning at 3:45 p.m. ET
• Location: Nasdaq MarketSite, Times Square, New York
• Event Livestream Link: https://www.nasdaq.com/marketsite/bell-ringing-ceremony

About Turn Therapeutics

Turn Therapeutics is a clinical-stage biotechnology company focused on developing targeted, localized therapies for inflammatory and infectious skin diseases. GX-03 is Turn Therapeutics' lead investigational topical candidate being developed as a targeted, non-systemic treatment for atopic dermatitis, designed to deliver biologic-level efficacy without the trade-offs of injectable administration or systemic immunosuppression. For more information, visit www.turntherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, contained in this press release are forward-looking statements, including statements regarding clinical development plans, optimization of enrollment criteria and endpoints, interpretation of interim clinical observations, expected trial timing, regulatory interactions, and the therapeutic potential of GX-03. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “suggest,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Turn Therapeutics’ current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict, including risks related to the success of development programs, the availability of additional financing, and the Company’s ability to execute its strategic plan. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Turn Therapeutics in general, see the risk disclosures in the Company’s filings with the SEC. All such forward-looking statements speak only as of the date they are made, and Turn Therapeutics undertakes no obligation to update or revise these statements, whether as a result of new information, future events, or otherwise.